Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: A longitudinal study

Thorax

Volumn 67, Issue 10, 2012, Pages 860-866

  Taylor Robinson, David ^a   Whitehead, Margaret ^a   Diderichsen, Finn ^b   Olesen, Hanne Vebert ^c   Pressler, Tania ^d   Smyth, Rosalind L ^a   Diggle, Peter ^e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^e LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DANISH; DISEASE REGISTRY; ETHNIC GROUP; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ERROR; POPULATION RESEARCH; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REFERENCE VALUE;

EID: 84866120215     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200953     Document Type: Article

References (34)

1. Holgate ST. Priorities for respiratory research in the UK. Thorax 2007;62:5-7. (Pubitemid 46101759)
2. Davies JC, Alton EW. Monitoring respiratory disease severity in cystic fibrosis. Respir Care 2009;54 :606-17.
3. Rabe KF, Hurd S, Anzueto A, et al Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55. (Pubitemid 47403272)
4. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134 e9, 139.e1.
5. Konstan MW, Schluchter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007;176:1084-9. (Pubitemid 350223754)
6. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6. (Pubitemid 23170123)
7. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91.
8. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342:d1008.
9. Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc 2007; 4:334-7. (Pubitemid 47330866)
10. Hnizdo E, Yu L, Freyder L, et al. The precision of longitudinal lung function measurements: monitoring and interpretation. Occup Environ Med 2005;62:695-701. (Pubitemid 41360895)
11. Stern DA, Morgan WJ, Wright AL, et al. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007;370:758-64. (Pubitemid 47320800)
12. van Diemen C, Postma D, Siedlinski M, et al. Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts. Respir Res 2011;12:57.
13. Harber P, Tashkin DP, Simmons M, et al. Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:994-1000. (Pubitemid 350127843)
14. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14. (Pubitemid 28027602)
15. Diggle P, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. 2nd edn. Oxford: Oxford University Press, 2002.
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
17. Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87. (Pubitemid 29036522)
19. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, New Jersey: Wiley, 2004.
20. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
21. Stanbrook MB, Corey M, Tullis DE. The repeatability of forced expiratory volume measurements in adults with cystic fibrosis. Chest 2004;125:150-5. (Pubitemid 38114577)
22. Hruby J, Butler J. Variability of routine pulmonary function tests. Thorax 1975;30:548-53.
23. Pennock BE, Rogers RM, McCaffree DR. Changes in measured spirometric indices. What is significant? Chest 1981;80:97-9. (Pubitemid 11002843)
24. Cooper PJ, Robertson CF, Hudson IL, et al. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 1990;8:16-22.
25. Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med 2004;169:235-8. (Pubitemid 38114540)
26. Rosenthal M. Annual assessment spirometry, plethysmography, and gas transfer in cystic fibrosis: do they predict death or transplantation. Pediatr Pulmonol 2008;43:945-52.
27. Mastella G, Rainisio M, Harms HK, et al . Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000;16:464-71.
28. Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8(Suppl 1): S15-19.
29. Vandevanter DR, Wagener JS, Pasta DJ, et al. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol 2010;45:1156-66.
30. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991;46:881-5.
31. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23. (Pubitemid 29251012)
32. MacLean JE, Atenafu E, Kirby-Allen M, et al. Longitudinal decline in lung volume in a population of children with sickle cell disease. Am J Respir Crit Care Med 2008;178:1055-9.
33. Kohansal R, Martinez-Camblor P, Agusti A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009;180:3-10.
34. Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-8. (Pubitemid 26127307)